BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22536362)

  • 1. Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence.
    Nickel GC; Barnholtz-Sloan J; Gould MP; McMahon S; Cohen A; Adams MD; Guda K; Cohen M; Sloan AE; LaFramboise T
    PLoS One; 2012; 7(4):e35262. PubMed ID: 22536362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic and histologic spatiotemporal evolution of recurrent, multifocal, multicentric and metastatic glioblastoma.
    Georgescu MM; Olar A
    Acta Neuropathol Commun; 2020 Feb; 8(1):10. PubMed ID: 32014051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution.
    Kim H; Zheng S; Amini SS; Virk SM; Mikkelsen T; Brat DJ; Grimsby J; Sougnez C; Muller F; Hu J; Sloan AE; Cohen ML; Van Meir EG; Scarpace L; Laird PW; Weinstein JN; Lander ES; Gabriel S; Getz G; Meyerson M; Chin L; Barnholtz-Sloan JS; Verhaak RG
    Genome Res; 2015 Mar; 25(3):316-27. PubMed ID: 25650244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation whole exome sequencing of glioblastoma with a primitive neuronal component.
    Xu G; Zheng H; Li JY
    Brain Tumor Pathol; 2019 Jul; 36(3):129-134. PubMed ID: 30715630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study.
    Tabone T; Abuhusain HJ; Nowak AK; ; Erber WN; McDonald KL
    J Clin Pathol; 2014 Jul; 67(7):550-5. PubMed ID: 24695838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Genomic Sequencing Reveals Different Evolutionary Patterns Between Locally and Distally Recurrent Glioblastomas.
    Yoon N; Kim HS; Lee JW; Lee EJ; Maeng LS; Yoon WS
    Cancer Genomics Proteomics; 2020; 17(6):803-812. PubMed ID: 33099481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep sequencing of multiple regions of glial tumors reveals spatial heterogeneity for mutations in clinically relevant genes.
    Kumar A; Boyle EA; Tokita M; Mikheev AM; Sanger MC; Girard E; Silber JR; Gonzalez-Cuyar LF; Hiatt JB; Adey A; Lee C; Kitzman JO; Born DE; Silbergeld DL; Olson JM; Rostomily RC; Shendure J
    Genome Biol; 2014 Dec; 15(12):530. PubMed ID: 25608559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spatiotemporal genomic architecture informs precision oncology in glioblastoma.
    Lee JK; Wang J; Sa JK; Ladewig E; Lee HO; Lee IH; Kang HJ; Rosenbloom DS; Camara PG; Liu Z; van Nieuwenhuizen P; Jung SW; Choi SW; Kim J; Chen A; Kim KT; Shin S; Seo YJ; Oh JM; Shin YJ; Park CK; Kong DS; Seol HJ; Blumberg A; Lee JI; Iavarone A; Park WY; Rabadan R; Nam DH
    Nat Genet; 2017 Apr; 49(4):594-599. PubMed ID: 28263318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Zooming in" on Glioblastoma: Understanding Tumor Heterogeneity and its Clinical Implications in the Era of Single-Cell Ribonucleic Acid Sequencing.
    Khalafallah AM; Huq S; Jimenez AE; Serra R; Bettegowda C; Mukherjee D
    Neurosurgery; 2021 Feb; 88(3):477-486. PubMed ID: 32674143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.
    Arthur LM; Turnbull AK; Renshaw L; Keys J; Thomas JS; Wilson TR; Lackner MR; Sims AH; Dixon JM
    Breast Cancer Res Treat; 2014 Aug; 147(1):211-9. PubMed ID: 25104442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors.
    Schäfer N; Gielen GH; Rauschenbach L; Kebir S; Till A; Reinartz R; Simon M; Niehusmann P; Kleinschnitz C; Herrlinger U; Pietsch T; Scheffler B; Glas M
    J Transl Med; 2019 Mar; 17(1):96. PubMed ID: 30894200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
    Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
    Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma.
    Tanaka S; Batchelor TT; Iafrate AJ; Dias-Santagata D; Borger DR; Ellisen LW; Yang D; Louis DN; Cahill DP; Chi AS
    Acta Neuropathol Commun; 2019 Apr; 7(1):66. PubMed ID: 31036078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene mutation profiling of primary glioblastoma through multiple tumor biopsy guided by 1H-magnetic resonance spectroscopy.
    Tang C; Guo J; Chen H; Yao CJ; Zhuang DX; Wang Y; Tang WJ; Ren G; Yao Y; Wu JS; Mao Y; Zhou LF
    Int J Clin Exp Pathol; 2015; 8(5):5327-35. PubMed ID: 26191234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming therapeutic resistance in glioblastoma: the way forward.
    Osuka S; Van Meir EG
    J Clin Invest; 2017 Feb; 127(2):415-426. PubMed ID: 28145904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma.
    Hoffman M; Gillmor AH; Kunz DJ; Johnston MJ; Nikolic A; Narta K; Zarrei M; King J; Ellestad K; Dang NH; Cavalli FMG; Kushida MM; Coutinho FJ; Zhu Y; Luu B; Ma Y; Mungall AJ; Moore R; Marra MA; Taylor MD; Pugh TJ; Dirks PB; Strother D; Lafay-Cousin L; Resnick AC; Scherer S; Senger DL; Simons BD; Chan JA; Morrissy AS; Gallo M
    Cancer Res; 2019 May; 79(9):2111-2123. PubMed ID: 30877103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
    Brunsell TH; Sveen A; Bjørnbeth BA; Røsok BI; Danielsen SA; Brudvik KW; Berg KCG; Johannessen B; Cengija V; Abildgaard A; Guren MG; Nesbakken A; Lothe RA
    Clin Colorectal Cancer; 2020 Mar; 19(1):e26-e47. PubMed ID: 31982351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic characterization of recurrent high-grade astroblastoma.
    Bale TA; Abedalthagafi M; Bi WL; Kang YJ; Merrill P; Dunn IF; Dubuc A; Charbonneau SK; Brown L; Ligon AH; Ramkissoon SH; Ligon KL
    Cancer Genet; 2016; 209(7-8):321-30. PubMed ID: 27425854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
    Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
    Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.